Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

778
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
778

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

When QTc Shrinks After Rhythm Conversion.

JACC. Case reports·2026
Same author

Comprehensive Genomic Profiling of Cutaneous Adnexal Carcinomas: A Genomic Landscape Study.

Dermatopathology (Basel, Switzerland)·2026
Same author

Atrial Fibrillation in Athletes: Mechanisms, Management, and Future Directions.

JACC. Case reports·2026
Same author

Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Cancer immunology, immunotherapy : CII·2026
Same author

Ionic and Cellular Basis of Antiarrhythmic Drug Therapy and Its Proarrhythmic Risks.

Cardiac electrophysiology clinics·2026
Same author

Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes.

Medical sciences (Basel, Switzerland)·2026
Same journal

Postoperative adjuvant eribulin in high-risk patients with soft tissue sarcoma: A retrospective study of eight cases.

Rare tumors·2026
Same journal

Palatal malignant peripheral nerve sheath tumor: A case report and review of literature.

Rare tumors·2026
Same journal

Durable remission of metastatic myxoid liposarcoma following the cautious addition of pembrolizumab to ongoing pazopanib treatment: A case report.

Rare tumors·2026
Same journal

Diagnostic utility of Ki-67 proliferation index, PSA, and other immunohistochemical markers in prostatic basal cell carcinoma: A review of 24 cases in the current literature and discussion on current treatment and diagnostics.

Rare tumors·2026
Same journal

Chronic myeloid leukemia presenting with isolated central nervous system lymphoid blast crisis: A case report.

Rare tumors·2026
Same journal

Bronchoscopy, surgery and radiation therapy for bronchial adenoid cystic carcinoma: A retrospective cohort study.

Rare tumors·2026
See all related articles

Related Experiment Video

Updated: Oct 25, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

Olaratumab's failure in soft tissue sarcoma.

Maroun Bou Zerdan1, Aram H Bidikian2, Ibrahim Alameh1

  • 1Division of Hematology and Oncology, Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.

Rare Tumors
|August 5, 2021
PubMed
Summary
This summary is machine-generated.

Olaratumab, a PDGFRα antagonist for soft tissue sarcomas, showed limited efficacy in a Lebanese tertiary care center, mirroring global findings. Treatment challenges include tumor heterogeneity and immunogenicity.

Keywords:
DoxorubicinMENAOlaratumabSoft tissue sarcomaleiomyosarcomaliposarcoma

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.8K

Related Experiment Videos

Last Updated: Oct 25, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.8K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Soft tissue sarcomas are rare, heterogeneous malignancies with limited treatment options.
  • Olaratumab (Lartruvo), a PDGFRα antagonist, was withdrawn from the market after disappointing Phase III trial results.

Purpose of the Study:

  • To evaluate the real-world experience of Olaratumab use in advanced/metastatic soft tissue sarcomas.
  • To compare findings with existing literature prior to the drug's market withdrawal.

Main Methods:

  • Retrospective analysis of 15 adult patients with advanced/metastatic soft tissue sarcomas treated with Olaratumab.
  • Data collected from a tertiary care center in Lebanon between January 2017 and December 2018.

Main Results:

  • Median progression-free survival (PFS) was 7.87 months; mean overall survival (OS) was 12.26 months.
  • Patients received a median of 4 cycles of Olaratumab, with a median treatment duration of 21.3 months.
  • Results were consistent with previously reported literature, indicating limited efficacy.

Conclusions:

  • Olaratumab's efficacy in soft tissue sarcomas appears limited, aligning with prior studies.
  • Tumor immunogenicity and heterogeneity present significant challenges in sarcoma treatment.
  • Further research into diverse management strategies is warranted.